Citigroup Maintains Buy on Eli Lilly and Co, Raises Price Target to $895
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Andrew Baum has maintained a Buy rating on Eli Lilly and Co (NYSE:LLY) and increased the price target from $675 to $895.

April 02, 2024 | 7:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on Eli Lilly and Co and raised the price target from $675 to $895.
The upgrade in the price target by a significant margin suggests a strong confidence in Eli Lilly's future performance and growth prospects. This endorsement from a major financial institution like Citigroup could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100